Erik Halvorsen

Chief Business Development Officer

As Chief Business Development Officer, Erik brings a wealth of experience in translational medicine and commercialization of healthcare innovation to Tissue Genesis. He has worked at or with some of the nation’s leading academic institutions and pharmaceutical, medical device and diagnostics companies. Erik also has partnered with investors to build and sustain new companies. Most recently, Erik has worked at pH Partners providing investment banking strategic guidance to investors and companies in the life sciences sector.

Prior to pH Partners, Erik served as founding Director of the Texas Medical Center’s Innovation Institute and TMCx Accelerator. The Institute and Accelerator became premier destinations for healthcare startups offering a combination of curriculum, a world-class advisory network and financial resources from the TMC Venture Fund. Under Erik’s leadership, the programs helped hundreds of companies secure funding, establish strong strategic partnerships and bring innovative medical products to clinicians and patients.

Before moving to Texas, Erik spent more than a dozen years in the Boston area. While in Boston, Erik directed numerous life sciences research and development  projects within the Harvard-affiliated hospitals and research institutes including as Executive Director of Technology & Innovation for Boston Children’s Hospital, and Director of Business Development for the Harvard Stem Cell Institute. Erik excels in his role as strategic advisor or board member to early stage companies. Some of the more notable start-ups he has provided strategic direction to include Tetraphase Pharmaceuticals, Claritas Genomics, OPENPediatrics, Jibo and FAR Biotechnology.

Erik earned a PhD in Neuropharmacology from the University of Virginia. He is a frequent speaker on innovation and trends in healthcare, and has received numerous awards and accolades including being named to the Top 40 Under 40 in Boston in 2011. A current member of the Forbes Technology Council, Erik also was named one of the Top 30 Chief Innovation Officers in healthcare in 2018.